Skip to main content

NEUROCRINE BIOSCIENCES INC

For the period ended Dec 31, 2024. Filed Feb 10, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 10, 2025

NBIX$169.14+0.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated Statements of Stockholders’ Equity

Common Stock · AdditionalPaid-In Capital · AccumulatedOtherComprehensive Income (Loss) · Retained Earnings (Accumulated Deficit) · Total Stockholders’ Equity
(in millions) · Shares · $
Balances at December 31, 202194.9$0.1$2,011.4$(1.7)$(635.8)$1,374.0
Net income————154.5154.5
Other comprehensive loss, net of tax———(6.2)—(6.2)
Cumulative-effect adjustment due to adoption of ASU 2020-06——(106.8)—74.5(32.3)
Stock-based compensation expense——173.1——173.1
Issuances of common stock under stock plans1.6—44.7——44.7
Balances at December 31, 202296.5$0.1$2,122.4$(7.9)$(406.8)$1,707.8
Net income————249.7249.7
Other comprehensive income, net of tax———14.9—14.9
Stock-based compensation expense——194.3——194.3
Issuances of common stock under stock plans2.2—65.3——65.3
Balances at December 31, 202398.7$0.1$2,382.0$7.0$(157.1)$2,232.0
Net income————341.3341.3
Other comprehensive income, net of tax———(1.2)—(1.2)
Stock-based compensation expense——195.5——195.5
Issuances of common stock under stock plans2.7—122.1——122.1
Repurchases of common stock under accelerated buyback agreements(2.0)—(145.0)—(155.0)(300.0)
Balances at December 31, 202499.4$0.1$2,554.6$5.8$29.2$2,589.7
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.